Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank.
clinical trial
conference report
glioblastoma
immunosuppression
immunotherapy
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
25 03 2021
25 03 2021
Historique:
pubmed:
29
12
2020
medline:
28
4
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
Cancer immunotherapy has made remarkable advances with over 50 separate Food and Drug Administration (FDA) approvals as first- or second-line indications since 2015. These include immune checkpoint blocking antibodies, chimeric antigen receptor-transduced T cells, and bispecific T-cell-engaging antibodies. While multiple cancer types now benefit from these immunotherapies, notable exceptions thus far include brain tumors, such as glioblastoma. As such, it seems critical to gain a better understanding of unique mechanistic challenges underlying the resistance of malignant gliomas to immunotherapy, as well as to acquire insights into the development of future strategies. An Immuno-Oncology Think Tank Meeting was held during the 2019 Annual Society for Neuro-Oncology Scientific Conference. Discussants in the fields of neuro-oncology, neurosurgery, neuro-imaging, medical oncology, and cancer immunology participated in the meeting. Sessions focused on topics such as the tumor microenvironment, myeloid cells, T-cell dysfunction, cellular engineering, and translational aspects that are critical and unique challenges inherent with primary brain tumors. In this review, we summarize the discussions and the key messages from the meeting, which may potentially serve as a basis for advancing the field of immune neuro-oncology in a collaborative manner.
Identifiants
pubmed: 33367885
pii: 6047273
doi: 10.1093/neuonc/noaa277
pmc: PMC7992879
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
356-375Subventions
Organisme : NINDS NIH HHS
ID : F32 NS073366
Pays : United States
Organisme : NINDS NIH HHS
ID : R00 NS082381
Pays : United States
Organisme : NINDS NIH HHS
ID : R35 NS105068
Pays : United States
Organisme : NINDS NIH HHS
ID : K99 NS082381
Pays : United States
Organisme : NIA NIH HHS
ID : K02 AG068617
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014236
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA221747
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Nature. 2018 May;557(7706):575-579
pubmed: 29769722
Cancer Discov. 2016 Dec;6(12):1382-1399
pubmed: 27663893
J Neurooncol. 2017 Sep;134(3):495-504
pubmed: 28382534
Neuro Oncol. 2015 Feb;17(2):266-73
pubmed: 25239666
Cancer Cell. 2017 May 8;31(5):711-723.e4
pubmed: 28486109
Oncoimmunology. 2015 Jan 22;4(3):e994374
pubmed: 25949916
Lancet Oncol. 2015 Nov;16(15):e534-e542
pubmed: 26545842
BMC Med Res Methodol. 2003 Nov 24;3:26
pubmed: 14633287
Cancer Cell. 2018 Apr 9;33(4):547-562
pubmed: 29634943
N Engl J Med. 2016 Dec 29;375(26):2561-9
pubmed: 28029927
J Transl Med. 2007 Feb 12;5:10
pubmed: 17295916
Front Pharmacol. 2019 Mar 27;10:200
pubmed: 30971917
Mol Ther Nucleic Acids. 2013 Jul 09;2:e105
pubmed: 23839099
J Neurosurg. 1979 Mar;50(3):305-11
pubmed: 422981
Acta Neuropathol. 2017 Aug;134(2):297-316
pubmed: 28332095
N Engl J Med. 2018 Aug 30;379(9):e14
pubmed: 30157404
Nat Genet. 2020 Mar;52(3):320-330
pubmed: 32025001
Neuroimage Clin. 2016 Dec 18;13:386-394
pubmed: 28116231
Clin Radiol. 2020 Jan;75(1):20-32
pubmed: 31371027
Acta Neuropathol Commun. 2019 Nov 29;7(1):203
pubmed: 31815646
J Exp Med. 2005 Dec 19;202(12):1627-33
pubmed: 16365146
Cancer Invest. 2012 Jan;30(1):27-37
pubmed: 22236187
Nature. 2019 Jan;565(7738):234-239
pubmed: 30568305
Nat Immunol. 2011 Jul 31;12(9):870-8
pubmed: 21804557
Acta Neuropathol. 2012 Nov;124(5):599-614
pubmed: 22825593
Front Oncol. 2019 May 21;9:374
pubmed: 31165039
J Clin Invest. 2017 Apr 3;127(4):1425-1437
pubmed: 28319047
Nat Rev Clin Oncol. 2017 Jun;14(6):365-379
pubmed: 28094262
Neuro Oncol. 2019 Jan 1;21(1):14-25
pubmed: 30346600
Clin Cancer Res. 2016 Mar 1;22(5):1161-72
pubmed: 26490306
Neuro Oncol. 2016 Sep;18(9):1199-208
pubmed: 27106405
JAMA Oncol. 2020 Jul 1;6(7):1003-1010
pubmed: 32437507
J Immunol. 2000 May 1;164(9):4826-34
pubmed: 10779791
Cancer Discov. 2020 Mar;10(3):371-381
pubmed: 31919052
Clin Cancer Res. 2019 Oct 1;25(19):5799-5807
pubmed: 31320597
Nature. 2011 Oct 05;478(7368):197-203
pubmed: 21976023
J Immunother Cancer. 2019 Oct 26;7(1):278
pubmed: 31655605
Nat Commun. 2019 Jul 18;10(1):3170
pubmed: 31320621
Cancer J. 2010 Jul-Aug;16(4):382-91
pubmed: 20693851
Sci Rep. 2020 Mar 20;10(1):5095
pubmed: 32198420
Mol Ther. 2018 Jan 3;26(1):31-44
pubmed: 29103912
Nat Commun. 2018 Oct 17;9(1):4313
pubmed: 30333482
Oncoimmunology. 2015 Mar 06;4(2):e988098
pubmed: 25949885
Front Immunol. 2019 Jul 03;10:1462
pubmed: 31333642
J Neurosurg. 2019 Sep 1;131(3):657-666
pubmed: 31473668
Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1540-E1549
pubmed: 29386395
Nat Med. 2019 Mar;25(3):477-486
pubmed: 30742122
J Natl Cancer Inst. 2016 Jun 22;108(11):
pubmed: 27335052
Nat Med. 2020 May;26(5):712-719
pubmed: 32341579
Neuro Oncol. 2017 Jul 1;19(7):918-929
pubmed: 28387831
Nat Commun. 2018 Jul 13;9(1):2724
pubmed: 30006565
Clin Cancer Res. 2018 Aug 15;24(16):3792-3802
pubmed: 29593027
Neuro Oncol. 2015 Nov;17 Suppl 7:vii9-vii14
pubmed: 26516226
Brain. 2012 Apr;135(Pt 4):1042-54
pubmed: 22418738
Cancer Res. 2011 Apr 1;71(7):2664-74
pubmed: 21324923
Invest New Drugs. 2020 Oct;38(5):1570-1579
pubmed: 32140889
Neuro Oncol. 2016 Feb;18(2):195-205
pubmed: 26323609
Nat Commun. 2018 Nov 7;9(1):4664
pubmed: 30405135
Cancer Immunol Immunother. 2014 Aug;63(8):847-57
pubmed: 24878890
Nat Biotechnol. 2020 Apr;38(4):420-425
pubmed: 32042168
Bioeng Transl Med. 2018 Jul 27;3(2):75-86
pubmed: 30065964
Nature. 2018 Feb 22;554(7693):538-543
pubmed: 29443964
JCO Precis Oncol. 2019 Mar 27;3:
pubmed: 32914038
Neuro Oncol. 2017 Jul 1;19(7):930-939
pubmed: 28387849
J Neurooncol. 2019 May;142(3):587-595
pubmed: 30806888
Nat Immunol. 2000 Dec;1(6):515-20
pubmed: 11101874
Mol Ther. 2011 Oct;19(10):1793-801
pubmed: 21505426
Neuro Oncol. 2020 Feb 20;22(2):180-194
pubmed: 31679017
AJR Am J Roentgenol. 2011 Dec;197(6):W992-W1000
pubmed: 22109345
Nature. 2014 Aug 21;512(7514):324-7
pubmed: 25043048
Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):17872-9
pubmed: 20923878
J Immunol. 2001 Feb 15;166(4):2717-26
pubmed: 11160337
Oncologist. 2019 May;24(5):671-679
pubmed: 30796152
Lancet Oncol. 2019 Aug;20(8):1083-1097
pubmed: 31221619
Clin Neurol Neurosurg. 2013 Feb;115(2):146-53
pubmed: 23237636
Nat Protoc. 2020 Apr;15(4):1507-1524
pubmed: 32103205
Nat Commun. 2019 Feb 4;10(1):567
pubmed: 30718505
Lancet Oncol. 2020 May;21(5):655-663
pubmed: 32251621
Neuro Oncol. 2015 Nov;17(11):1514-24
pubmed: 26113557
Cell. 2020 Jun 25;181(7):1643-1660.e17
pubmed: 32470396
Cell Rep. 2019 Jul 30;28(5):1127-1135.e4
pubmed: 31365858
Sci Transl Med. 2016 Jun 1;8(341):341ra75
pubmed: 27252174
Cancer Res. 2007 Oct 15;67(20):9630-6
pubmed: 17942891
Cancer Res. 2016 Oct 1;76(19):5671-5682
pubmed: 27530322
Clin Cancer Res. 2018 Jun 15;24(12):2951-2962
pubmed: 29563135
Sci Rep. 2018 Jul 31;8(1):11470
pubmed: 30065314
Nature. 2019 Jan;565(7738):240-245
pubmed: 30568303
Cancers (Basel). 2020 Feb 27;12(3):
pubmed: 32120803
Clin Cancer Res. 2007 Dec 1;13(23):7155-65
pubmed: 18056196
Nat Commun. 2020 May 8;11(1):2283
pubmed: 32385241
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
JCI Insight. 2016;1(2):
pubmed: 26973881
Clin Cancer Res. 2012 Nov 15;18(22):6110-21
pubmed: 22932670
Cancer Cell. 2018 Apr 9;33(4):563-569
pubmed: 29634944
Clin Cancer Res. 2019 Oct 1;25(19):5743-5751
pubmed: 31040150
J Natl Cancer Inst. 2018 Oct 1;110(10):1123-1132
pubmed: 29788332
Clin Cancer Res. 2019 Jan 1;25(1):290-299
pubmed: 30279232
Neuro Oncol. 2013 Jul;15(7):891-903
pubmed: 23595625
Oncoimmunology. 2017 Mar 31;6(5):e1308616
pubmed: 28638730
Nat Rev Immunol. 2018 Apr;18(4):225-242
pubmed: 29151590
Clin Cancer Res. 2018 Jan 1;24(1):95-105
pubmed: 29061641
Front Oncol. 2019 Feb 22;8:656
pubmed: 30854331
Neuro Oncol. 2020 Apr 15;22(4):539-549
pubmed: 31755915
Nat Med. 2018 Nov;24(11):1649-1654
pubmed: 30297909
Neuro Oncol. 2019 Jan 1;21(1):95-105
pubmed: 30277538
Oncoimmunology. 2017 Nov 7;7(2):e1391972
pubmed: 29308320
J Transl Med. 2006 Mar 30;4:15
pubmed: 16573834
Neuro Oncol. 2018 Sep 3;20(10):1383-1392
pubmed: 29762717
Nature. 2019 Jul;571(7764):211-218
pubmed: 31207603
Cancer Res. 2007 Jul 1;67(13):6451-8
pubmed: 17616706
Clin Cancer Res. 2018 Feb 15;24(4):737-743
pubmed: 28814435
J Exp Med. 2003 Dec 1;198(11):1741-52
pubmed: 14657224
Neuro Oncol. 2015 Feb;17(2):174-6
pubmed: 25452393
Nat Med. 2020 Jan;26(1):39-46
pubmed: 31873309
Mol Ther. 2017 Dec 6;25(12):2620-2634
pubmed: 28967558
Sci Transl Med. 2017 Jul 19;9(399):
pubmed: 28724573
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Nat Commun. 2019 Sep 5;10(1):4016
pubmed: 31488817
Neuron. 2018 Jun 27;98(6):1170-1183.e8
pubmed: 29861285
Cell Mol Immunol. 2018 May;15(5):447-457
pubmed: 29375124
Nat Med. 2018 Dec;24(12):1852-1858
pubmed: 30478423
J Biomed Biotechnol. 2010;2010:350748
pubmed: 20224643
J Nucl Med. 2017 Apr;58(4):538-546
pubmed: 27980047
Proc Natl Acad Sci U S A. 2016 May 17;113(20):5592-7
pubmed: 27143722
Clin Cancer Res. 2009 Nov 1;15(21):6560-9
pubmed: 19861451
J Immunother. 2009 Apr;32(3):240-51
pubmed: 19242376
Neuro Oncol. 2018 May 18;20(6):826-837
pubmed: 29165638
Nat Med. 2018 Aug;24(8):1192-1203
pubmed: 29988124
Trends Immunol. 2007 Jan;28(1):12-8
pubmed: 17129764
PLoS One. 2011;6(5):e19662
pubmed: 21637760
BMC Cancer. 2018 Mar 1;18(1):239
pubmed: 29490632
Mol Ther. 2009 Jan;17(1):199-207
pubmed: 18957964
Neuro Oncol. 2018 Jun 18;20(7):873-884
pubmed: 29432615
J Nucl Med. 2020 Apr;61(4):512-519
pubmed: 31586002
Neurotherapeutics. 2017 Apr;14(2):307-320
pubmed: 28108885
J Immunother Cancer. 2016 Sep 20;4:58
pubmed: 27660712
J Clin Oncol. 2018 May 10;36(14):1419-1427
pubmed: 29432077
Neuroscience. 1996 Sep;74(2):599-608
pubmed: 8865208
Neuro Oncol. 2016 Aug;18(8):1146-56
pubmed: 26902851
Lancet Oncol. 2017 Oct;18(10):1373-1385
pubmed: 28844499
Int J Cancer. 2007 Mar 1;120(5):978-84
pubmed: 17163419
Oncoimmunology. 2018 Sep 5;7(12):e1501137
pubmed: 30524896
Nat Med. 1996 Oct;2(10):1096-103
pubmed: 8837607
Cancer Immunol Res. 2016 Jun;4(6):498-508
pubmed: 27059623
J Neurosurg. 2005 Sep;103(3):428-38
pubmed: 16235673
Cell. 2020 Jun 25;181(7):1626-1642.e20
pubmed: 32470397
Genome Biol. 2017 Dec 20;18(1):234
pubmed: 29262845
J Med Life. 2014 Oct-Dec;7(4):572-6
pubmed: 25713625
Cancer Cell. 2019 Jun 10;35(6):868-884.e6
pubmed: 31185211
Cell. 2018 May 31;173(6):1426-1438.e11
pubmed: 29706540
N Engl J Med. 2018 Jul 12;379(2):150-161
pubmed: 29943666
Nat Med. 2018 Sep;24(9):1459-1468
pubmed: 30104766
J Clin Oncol. 2002 Aug 15;20(16):3424-30
pubmed: 12177102
Nat Med. 2018 Nov;24(11):1655-1661
pubmed: 30297911
J Clin Invest. 2020 Dec 1;130(12):6325-6337
pubmed: 32817593
Cell. 2019 Oct 31;179(4):880-894.e10
pubmed: 31668804
Front Immunol. 2018 Aug 15;9:1838
pubmed: 30158927
Immunol Rev. 2017 Mar;276(1):121-144
pubmed: 28258700
N Engl J Med. 2018 Aug 23;379(8):722-730
pubmed: 30134131
PLoS Pathog. 2015 Oct 20;11(10):e1005177
pubmed: 26485519
Neurosci Lett. 2016 Sep 6;630:203-208
pubmed: 27493076